



Inside Today's Blitz

- Eurozone Bond Yields Surge on Reports of 50bps Hike this Week
- China COVID Cases Surge
- **IBM** Beats Estimates but Cash Flow Guidance Disappoints; **HAL** Profits Jump on Drilling Demand; **NCR** in discussions for PE Deal

Market Outlook

Futures are moving strongly higher early with risk-on activity across crypto with the US Dollar firmly lower after reports of a more hawkish ECB move. VIX futures are falling hard back under 25 while Oil is also down 2% with soft commodities mostly lower as well. Cautious outlooks from Tech giants Apple and IBM yesterday reversed an early Tech rally and more results expected across the sector in the coming week. Earnings commentary remains mixed thus far but sentiment/positioning into earnings season is at a bearish extreme.

European stocks were mostly higher in choppy trade on Tuesday despite reports of a spending slowdown at tech giant Apple and a mixed earnings update from IBM. Eurostat data showed that the region's inflation accelerated as estimated in June to set a fresh record high, driven by higher energy and food prices and now a growing consensus of a larger ECB rate hike this week. The euro hit a two-week high and bonds slid across Europe.

Asian stocks ended lower on Tuesday as investors showed growing concerns about earnings in the face of a tougher macro environment. Covid-19 cases in China jumped to 699 on Monday - the highest daily tally since May 22. China's central bank injected additional liquidity into the financial system for the first time since June as authorities try to prevent a crisis of confidence in the housing market. Kawasaki Heavy Industries surged 5.2 percent and Mitsubishi Heavy Industries rallied 2.5 percent after the Nikkei reported that the government will forego setting a ceiling on defense spending in next fiscal year's annual budget. Australian markets fell as the minutes of the RBA's July meeting showed the board remains committed to doing what is necessary to curb inflation.

Calendar


Today... Housing Starts; Earnings from ALLY, CFG, HAL, HAS, HTLD, JNJ, LMT, MAN, NVS, SBNY, SI, TFC, CALM, FULT, HWC, HOPE, IBKR, JBHT, NBHC, NFLX, OMC, PNFP, UCBI; BOE Gov Bailey Speaks, RBA Gov Lowe Speaks, UK CPI, Eurozone Final CPI, Construction Output

Tomorrow... Existing Home Sales, Crude Oil Inventories; Japan Outlook Report and Press Conference. ECB Current Account, Eurozone Consumer Confidence. Germany PPI; Earnings from ABT, ASML, BIIB, ELV, AA, CCK, CSX, DFS, EFX, LVS, TSLA, STLD; Analyst Meetings at CPRI, CAL, CALM, ADBE

Overnight Markets

| Description | Price | Change |
|-------------|--------|--------|
| Natural Gas | 7.39 | -1.35% |
| Copper | 3.305 | -1.20% |
| Oil (WTI) | 97.8 | -1.63% |
| Silver | 18.81 | -0.16% |
| Gold | 1714.3 | 0.24% |
| US Dollar | 106.5 | -0.80% |
| VIX | 24.9 | -3.00% |
| Bonds | 118.22 | -0.21% |
| Bitcoin | 22,020 | 1.85% |
| Etherium | 1,540 | 4.65% |

Technical View



Key Levels to Watch

S&P Futures (ES_F) traded higher overnight back above the key gamma level of 3840. Yesterday's decline found support at July monthly VWAP of 3830 so that will be a big line in sand the remainder of the week. Daily value area low at 3854.5 and above that could retest daily VPOC at 3892.25 with the round number 3900 just above that. On follow through higher the 3940 level becomes resistance.

Economic Data

- **UK** unemployment rate remained unchanged in three months to May at 3.8%
- **Eurozone** inflation accelerated to a new record high, as estimated in June, while core inflation eased slightly, final data from Eurostat showed on Tuesday

Macro News

- **Treasuries** - Japan and China pared back holdings of U.S. Treasuries in May to multi-year lows, data from the U.S. Treasury department showed on Monday. The world's second largest economy has reduced holdings Treasuries for six straight months. In other asset classes, foreigners sold U.S. equities in May for a fifth straight month amounting to \$9.15 billion, from outflows of \$7.04 billion in April.
- **ECB** – Bloomberg reporting that The European Central Bank may consider raising interest rates on Thursday by double the quarter-point it outlined just last month because of the worsening inflation backdrop
- **Singapore** - Singapore's economic growth is expected to moderate further next year, tracking a slowdown in its major trading partners, while global inflation is expected to ease in 2023, the head of the city-state's central bank said on Tuesday
- **China** - China vowed to take a “resolute and strong” response to any Taiwan visit by US House speaker Nancy Pelosi, setting the stage for a possible showdown over the reported landmark trip

Movers

Gainers: APLS 24%, NCR 11.5%, WFG 15%, LPX +8%, SI 7%, COIN 3%, SHO +7.6%, TXG +6.3%, MLCO +5%, MRTN 2.5%, FWRD 3%

Losers: DLO -4.3%, IBM -5.7%, DOCN -3.3%. GBT -3%, ASAN -5%, FSLY -4.8%. LMT -4.5%

Insider Buying

ET, VOXX, MEDP

IPO Calendar

Virax Biolabs (VRAX) to IPO
1.35M Shares at \$5

MARKET HEALTH AND STATS CHECK

| INDICATOR | SIGNAL |
|-------------------------------|--------|
| NYSI | BULL |
| WEEKLY MACD | BEAR |
| 8/21 WEEKLY MA | BEAR |
| CUMUALTIVE A/D 89-EMA | BEAR |
| NEW HIGH/LOW CUMULATIVE 10-MA | BEAR |
| UP/DOWN VOLUME RAITO 150-MA | BEAR |
| TOP OF BOOK DEPTH | BEAR |
| YTD EQUITY FLOWS | +211B |
| IMPLIED FRR | 4.50% |

Sentiment

- **Equity Funds** - U.S. equity funds witnessed a record erosion in their net assets in the second quarter of this year, as stocks slumped due to soaring inflation and rising expectations of aggressive rate hikes by major central banks
- **BAML Survey** - Investors slashed their exposure to risk assets to levels not seen even during the global financial crisis in a sign of full capitulation amid a “dire” economic outlook, according to Bank of America Corp.’s monthly fund manager survey. Global growth and profit expectations sank to an all-time low, while recession expectations were at their highest since the pandemic-fueled slowdown in May 2020. Investor allocation to stocks plunged to levels last seen in October 2008 while exposure to cash surged to the highest since 2001, according to the survey. A net 58% of fund managers said they’re taking lower than normal risks, a record that surpassed the survey’s global financial crisis levels.

Stock-Specific News

Consumer Goods (XLP)

- Activist fund manager Bluebell Capital Partners is seeking changes to the board at **Richemont**

Consumer / Business Services (XLY)

- Capital Group cut its valuation on **Instacart Inc.** to \$14.7 billion, which is far below the company’s own calculation of \$24 billion, according to Bloomberg. The grocery-delivery platform slashed its internal valuation by approximately 40% since its March 2021 funding round (\$39 billion) amid slowing growth, surging inflation and higher interest rates
- **VRRM** expands its European operations with new contract wins, partnerships and strategic memberships
- **Sunstone Hotel Investors (SHO)** will replace **Vonage Holdings (VG)** in the S&P SmallCap 600
- **SBUX** aiming to close more stores due to crime and drug use, Bloomberg reports
- **Internet Brands** has completed a recapitalization with its long-term investors KKR and Temasek, and a group of new investors led by

Warburg Pincus, at a valuation of more than \$12 billion. KKR will remain the majority investor in the company.

- **Hotel Chocolat** boss warns on profits next year despite revenue exceeding expectations

Financials (XLF)

- **NCR** is in exclusive talks to be sold to private-equity firm Veritas Capital, the WSJ reports. A deal could still be weeks away, the people said, and it's far from guaranteed, given that a number of LBOs have been shelved lately because of choppy financing markets.
- **MTB** authorizes \$3B buyback
- **JEF** expects to spin off to its shareholders its holdings in Vitesse Energy prior to the end of 2022
- **Swedbank** reported a smaller-than-expected net profit for the second quarter on Tuesday, as higher costs and lower trading gains took some of the shine off rising income from mortgages on the back of higher interest rates
- **Wise** shares higher by 14% after it posted a sharp rise in revenues and customer transactions

Healthcare (XLV)

- **MRK** will stop for futility the Phase 3 LYNK-003 trial investigating LYNPARZA with or without bevacizumab for the treatment of patients with unresectable or metastatic colorectal cancer who have not progressed following first-line induction
- **INCY** today announced that the U.S. Food and Drug Administration (FDA) has approved Opzelura™ (ruxolitinib) cream 1.5% for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older
- **ACAD** Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome
- **RARE** provided a program update on GTX-102 for the treatment of Angelman syndrome, or AS, including interim data from the open-label, dose-escalating Phase 1/2 study in pediatric patients who have a genetically confirmed diagnosis of full maternal UBE3A gene deletion. Interim results on nine patients from the U.K./Canada arm and two patients from the U.S. arm of the Phase 1/2 study demonstrate a meaningful improvement in clinical disease and an acceptable safety profile
- **APLS** PDUFA set for 11/26/2022 Priority Review designation for the intravitreal pegcetacoplan New Drug Application
- **AXGN** boosts guidance

Hawk Database

NCR buyer 20,000 Aug. 31/38 call spreads yesterday

On the Chart

INCY flagging on 21-MA and could see some momentum on a move over 81

Hawk Database

IRTC August \$140/\$60 call spreads bought 1000X on 7/13 and remain in OI

- EU aiming to reschedule coronavirus vaccine deliveries to 2024 due to surplus of shots
- **IRTC** sees Q2 revenues in-line, guides unit volumes ahead of expectations
- **ILMN** - EU Commission alleges Illumina and GRAIL breached EU merger rules by early implementation of their acquisition
- **VKTX** announces FDA has lifted clinical hold on Phase 1b trial of VK0214 in patients with X-ALD

Hawk Database

ILMN has seen a lot of put buying and remains a top bear flow name

Industrials (XLI)

- **FWRD** guides Q2 EPS and Revenues strongly above estimates
- **Chase (CCF)** entered into a definitive agreement to acquire NuCera Solutions from SK Capital, a company in production and development of highly differentiated specialty polymers and polymerization technologies serving demanding applications. The deal is valued at \$250M
- **LILM** has signed an agreement with AAP Aviation Group AS to develop an eVTOL network in Scandinavia. Under the agreement, AAP Aviation intends to purchase 40 Lilium Jets and collaborate with Lilium to identify and develop landing sites in the Scandinavian countries, starting with Norway
- **UPS** opened a second airport cargo-handling facility in India to capture soaring pandemic-driven demand for airfreight
- **Volvo** on Tuesday posted a bigger-than-expected rise in profit helped by strong demand for its trucks, but warned of continued supply chain issues. A global shortage of components such as semiconductors and a lack of freight capacity have pressured truck makers after markets began to recover from the pandemic-induced demand slump.
- **Alstom** shares slumped after the French train maker warned that red-hot inflation will slightly weigh on its annual profits.

Materials & Energy (XLB, XLE)

- **WFG** - Private equity firm CVC Capital and wood panel manufacturer Kronospan have submitted a joint expression of interest to acquire Canadian lumber company West Fraser Timber Co, Reuters reports.
- **BHP** will accelerate the start of a \$5.7 billion potash project in Canada as high gas prices and curbs on key exporters disrupt fertilizer supply chains

- **Ampol**, Australia's biggest fuel supplier, Tuesday posted an over five-fold increase in refining margin at its Lytton Refinery in Queensland for the second quarter as prices of refined products surged amid rising demand
- **EV Batteries** - Solid-state batteries could cut the carbon footprint of electric vehicle (EV) batteries by 29% compared with today's liquid lithium-ion batteries and could reduce it even further using sustainably sourced materials, a campaign group said on Tuesday
- **Yara**, one of the world's biggest fertiliser producers, warned there could be shortages of nitrogen-based fertilisers due to high gas prices as it reported a higher than expected second-quarter profit
- **Petra Diamonds** on Tuesday reported a 44% jump in full-year revenue to \$585.2 million, driven by higher gem prices, an increase in exceptional stones and record jewellery demand in the United States

Sympathy Mover

QS is developing solid-state lithium metal batteries for electric vehicles

Technology (XLK)

- SoftBank has put on hold plans for a London initial public offering of the British chip technology firm **Arm Ltd** because of the political turmoil in the UK government

Communications & Utilities (XLU, XLC)

- **Electricite de France** leaped on Tuesday after the French government said it will pay just under \$10 billion to buy out minority shareholders in Europe's largest power generator
- **Telenor** on Tuesday reported second-quarter earnings slightly above forecasts and reiterated its outlook, though it will try to bring rising costs under control in the second half of the year

Analyst Notes

Upgrades

- **XOM** raised to Overweight at Piper expecting solid downstream performance and resilience from the chemicals unit
- **BAP** raised to Outperform at CSFB seeing healthy earnings growth and Peru a more defensive country in Latin America
- **CNK** raised to Overweight at MSCO seeing movie-going picking up as a counter-cyclical form of entertainment

On the Chart

XOM close over 88 can start a new trend higher move

- **CBOE** raised to Overweight from Underweight at MSCO with the transaction-heavy model having upside potential and high-margin index options business
- **TAK** raised to Outperform at Cowen on valuation given strong cash flows, dividend yield
- **OVV, COP, EOG, SWN, CNQ** raised to Buy at BAML
- **ANET** raised to Buy at Needham as insulated company with heavy cloud exposure

Hawk Database

CBOE 1200 Nov. \$125 calls in OI from buyers in April, needs to clear 121

Downgrades

- **BECN** cut to Neutral at Blair
- **STEP, APO** cut to Neutral at MSCO
- **FNV** cut to Underweight at Barclays with macro and fundamental headwinds
- **ASAN, FSLY** cut to Underperform at RBC with worrisome cash burn and lack of profitability
- **RUN, NOVA** cut to Neutral at Piper
- **CRC, DNR, PXD** cut to Underperform at BAML
- **SQ** cut to Hold at Macquarie

Hawk Database

FNV opening sale 1000 Oct. \$135 calls 7/18 and chart breaking support

Initiations

- **FTHM** started Overweight at Stephens
- **CASY** started Buy at Benchmark on proven growth model and competitive position is enhanced by its focus on smaller markets
- **TASK** started Buy at Citi citing cheap valuation to peers with industry-leading growth
- **APLS** started Buy at HCW as expects Apellis's C3 inhibitor, pegcetacoplan, to be approved and become a blockbuster in geographic atrophy with peak sales of over \$2B
- **AMCR** started Buy at CLSA with portfolio that offers defensive earnings growth with an effective inflation hedge

Hawk Database


APLS 2000 Jan. \$60 calls bought on 1/3/22 remain in OI

Other Notes

- -

Trade Ideas

Lennar (LEN) shares are forming a bull flag on top of the 8/21 EMA's after a strong reversal candle last week off support near 75. On Monday the stock had an inside day candle which creates a good level to trade against and trigger a buy above the high at 79. An upside breakout can see a move to 83.70 YTD VWAP and possibly a higher target eventually at 86 which is a naked VPOC.



Technical Scans

Inside Day Candle: NEE, CVS, KHC, DLTR, EXC, DHI, LEN, KNX, PHM, BALL, TXRH, VERU, PEG, ACI, PNR

Bearish MACD Cross: GOOG, HSY, ODFL, KO, MSCI, ZTO, MDB, CAG, DRE, PLUG, QDEL, RUN, EXEL, NVAX, OLLI, AI, NOVA, MTOR, LW, CFLT

8/21 EMA Bull Cross: AMZN, MA, TXN, C, NFLX, FISV, ROST, ON, KBR, SYF, LEVI, DOX, ELY, FOX, CHGG, HLF, WWW, STNG, BSY, WES, COUR

50 Day Lows: LMT, CB, SYK, TRV, DLR, CHT, MKC, HIG, PARA, NRG, AIZ, IIPR, MCY, NEGG, CINF, STAG

Earnings Preview

Nucor (NUE) is reporting earnings on 7/21 before the market opens and the Street is looking for \$8.61 EPS/\$11.514B in sales. Shares have closed higher 5 of the last 8 reports and higher the last 2 with a median closing move of +0.91% and average max move of 5.5%. Current implied move is 5.7%. The average IV crush for earnings is about -4.1%. Historical put/call OI percentile sits at 87.1%. Short interest at 3.1%. NUE shares are now flat YTD after a wild move to highs in the Spring followed by a sharp decline lower with steel and commodity-based groups selling off. The stock recently made a low near 100 and has recovered to near 115 which is the monthly VPOC resistance. Lots of overhead congestion also in the form of the 200- and 55-day EMA's at the 120 level. NUE is bouncing off yearly VPOC support near 103 but potential for a bear flag to form and a retest of lows as weekly MACD is still in bear trend mode. The \$30.5B company trades 9.6X earnings, 1.0X sales and a FY23 FCF yield of 6.9% with a 1.8% dividend yield. Revenues are expected to grow +15% in the current fiscal year and slow to -19% in FY23 with fears of recession hurting steel demand. NUE is focused on manufacturing steel and steel products that produce direct reduced iron for use in its steel mills. In June, the company provided bullish Q2 guidance easing concerns over rising rates and inflation. Nucor specifically mentioned it continues to see robust demand in nonresidential construction markets, a sentiment it has held for several quarters. Analysts have an average target for shares of \$249 with a Street High \$278. On 7/6, Morgan Stanley lowered their price target to \$121 from \$144 amid the sharper than expected fall in steel prices from the March highs and they reduced estimates for steel and scrap price forecasts into 2023. Options flows have been mostly bearish leaning in open interest with January \$110 puts opened on 7/7 at \$15 for over \$1.5M and October \$135 calls sold to open 1000x recently for \$14.10.

Trade to Consider: Sell NUE August 120/125 call spread at \$1.66 or better

Small Cap Profile

Immunocore (IMCR) a standout chart in Biotech with shares flagging below \$46 and higher by 31% while 600 August \$50 calls bought at \$2.90 to \$3.50 on 7/18 with IV30 currently at 113.5%.

IMCR is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. IMCR is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Unlike antibody targeted immunotherapies that have a relatively small target pool, IMCR approach relies on the power of T cell receptors, or TCRs, which are naturally occurring receptors found on the surface of T cells that have the ability to target nearly all of the human proteome. Natural TCRs give T cells the ability to scan for abnormalities in nearly any cell in the body that are presented as protein fragments, or antigens, by human leukocyte antigen, or HLA, on the cell surface. ImmTAX bispecific therapeutics couple the targeting power of these engineered TCRs on one end with the other end displaying pre-optimized effector functions, which have the ability to drive a desired immune response at the site of the disease.

On January 26, 2022, the U.S. Food and Drug Administration, or the FDA, approved KIMMTRAK (tebentafusp-tebn) for the treatment of patients with unresectable or metastatic uveal melanoma, or mUM. KIMMTRAK is the first TCR therapeutic to receive regulatory approval from the FDA, the first bispecific T cell engager to receive regulatory approval from the FDA to treat a solid tumor, and the first and only therapy for the treatment of unresectable or mUM to be approved by the FDA. IMCR shares have shown strength since February when the company received a positive CHMP opinion for KIMMTRAK for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM). Phase 1 data updates are expected on ImmTAC compounds IMC-F106C targeting PRAME in mid-2022 and IMC-C103C targeting MAGE-A4 in 2H22 that could further derisk compounds with potential peak annual revenues of \$5B with additional upside potential on ImmTAV and ImmTAAI compounds in the years ahead.

IMCR has a market cap of \$1.94B and trades 8X Cash with revenues seen rising 155% in 2022. Baker Brothers is the 2nd largest holder.



Open Interest Checks

| Ticker | Contract | Prior OI | New OI | OI Change |
|--------|---------------------|----------|--------|-----------|
| FCX | 19 AUG 22 30 CALL | 6,339 | 15,371 | 142.48% |
| LEVI | 20 JAN 23 22 CALL | 2,235 | 5,161 | 130.92% |
| DIS | 16 SEP 22 110 CALL | 3,505 | 7,352 | 109.76% |
| DXCM | 19 AUG 22 85 PUT | 950 | 1,950 | 105.26% |
| FSR | 21 OCT 22 10 PUT | 5,022 | 10,059 | 100.30% |
| NVDA | 16 SEP 22 135 PUT | 2,630 | 5,217 | 98.37% |
| SBSW | 20 JAN 23 12.5 CALL | 4,028 | 7,712 | 91.46% |
| AAPL | 16 SEP 22 155 PUT | 15,572 | 29,662 | 90.48% |
| SCHW | 19 JAN 24 55 PUT | 2,642 | 4,288 | 62.30% |
| LYFT | 21 OCT 22 15 CALL | 13,269 | 20,913 | 57.61% |
| NVDA | 16 SEP 22 155 CALL | 1,421 | 2,098 | 47.64% |
| COP | 19 AUG 22 90 CALL | 4,678 | 6,899 | 47.48% |
| TWTR | 16 SEP 22 33 PUT | 4,016 | 5,310 | 32.22% |
| NVDA | 21 OCT 22 200 CALL | 3,491 | 4,491 | 28.65% |
| UAL | 17 MAR 23 50 CALL | 2,694 | 1,655 | -38.57% |
| SWIR | 16 SEP 22 22.5 CALL | 4,312 | 2,188 | -49.26% |
| OXY | 20 JAN 23 70 CALL | 13,439 | 5,280 | -60.71% |
| MRVL | 16 SEP 22 42.5 CALL | 14,202 | 4,520 | -68.17% |

Extras

Infosys (INFY) buyer 1500 August \$19 puts to open for \$1

Ross (ROST) buyer 800 January \$70 puts for \$4.50

What They're Saying

IBM Earnings Call on demand trends... "Demand for our solutions remains strong. We continue to have double-digit performance in IBM Consulting, broad-based trend in software. And with the z16 platform launch, our infrastructure business had a good quarter. Security revenue was up 5% with growth in threat management and identity as enterprises continue to adopt a Zero Trust security strategy and implement additional identity controls. We're continuing to invest in our security capabilities, having completed 2 acquisitions in the threat management space over the last few quarters. Automation revenue was up 8%. Solid performance in both AI ops and management and integration demonstrates the importance of automation in the IT journeys of our clients. Data & AI revenue grew 4%. This growth was led by demand for data fabric, data management and asset and supply chain management solutions. Consulting's hybrid cloud revenue grew 32% over the last year to \$8.6 billion. Momentum behind our Red Hat practice remains strong. We nearly doubled our Red Hat consulting revenue in the quarter and continued solid Red Hat bookings, which now exceeds \$6 billion inception to date. Application operations revenue grew 17%. Growth was solid across our cloud offerings, mitigated by declines in the on-prem space. Distributed infrastructure revenue grew 17% this quarter. This growth was led by storage, driven by both high-end storage tied to the z16 cycle and distributed storage."

Earnings Grid

| Stock | Next Earn | | Open Interest | Historical Moves (8 Q) | Avg. 8 Q | | | Med. 8 Q | | | Sum. 8 Q | | | Hist | | SI |
|-------|-----------|------|---|------------------------------|--------------|----------|------------|------------|------------|-----------|----------------|--------------------|-------------|--------------|--|----|
| | Date | Time | | | Implied Move | Max Move | Close Move | Close Move | Close Move | IV30 Skew | IV30 Avg Crush | Put/Call OI %-tile | Short Float | Change (3mo) | | |
| IBM | 7/18/2022 | AMC | Bear: \$16.27M (54%), Bull: \$12.91M (43%), Stock: \$1.13M (4%) | Even of 8, Higher last 2 | 5.38% | 7.10% | 0.62% | -8.19% | 5.7 | -24.10% | 19.75% | 2.49% | 2.44% | | | |
| MRTN | 7/18/2022 | AMC | No Trades Since Last Report | Even of 8, Higher last 3 | 7.76% | 8.63% | 1.92% | 2.83% | 0.05 | -13.40% | 79.75% | 3.43% | 0.51% | | | |
| JNJ | 7/19/2022 | BMO | Bull: \$11.35M (85%), Bear: \$2.08M (15%) Bull: \$9.66M (58%), Bear: \$4.87M (29%), Stock: \$1.23M (7%), Vol: \$0.81M (5%) | Higher 7 of 8, Higher last 6 | 2.39% | 2.92% | 2.34% | 12.30% | 4.12 | -10.30% | 84.97% | 0.54% | -0.77% | | | |
| LMT | 7/19/2022 | BMO | | Lower 6 of 8 | 3.86% | 4.41% | -2.31% | -18.30% | 6.37 | -5.51% | 46.03% | 0.97% | -29.32% | | | |
| HAL | 7/19/2022 | BMO | Bull: \$6.72M (58%), Bear: \$3.74M (33%), Stock: \$1.03M (9%) | Even of 8 | 7.22% | 4.80% | -0.16% | 4.34% | 4.98 | -4.84% | 43.66% | 1.89% | 31.18% | | | |
| HAS | 7/19/2022 | BMO | Bear: \$18.2M (72%), Bull: \$6.28M (25%), Stock: \$0.67M (3%) | Even of 8 | 8.01% | 7.18% | 0.20% | 0.01% | 7.91 | -24.60% | 69.57% | 3.49% | -17.15% | | | |
| ALLY | 7/19/2022 | BMO | Bull: \$4.26M (51%), Bear: \$4.14M (49%) | Even of 8, Lower last 3 | 9.51% | 5.27% | -1.88% | -8.36% | 10.2 | -10.50% | 93.66% | 2.72% | 14.30% | | | |
| MAN | 7/19/2022 | BMO | No Trades Since Last Report | Lower 5 of 8, Higher last 2 | 7.96% | 5.80% | -2.76% | -4.66% | 6.19 | -13.50% | 69.63% | 3.19% | 26.52% | | | |
| NFLX | 7/19/2022 | AMC | Bull: \$63.1M (51%), Bear: \$55.81M (45%), Stock: \$5.74M (5%) | Lower 7 of 8, Lower last 5 | 12.54% | 14.30% | -6.72% | -66.30% | 8.6 | -18.54% | 22.05% | 2.95% | 64.27% | | | |
| JBHT | 7/19/2022 | AMC | Bear: \$2.17M (56%), Bull: \$1.73M (44%) | Higher 5 of 6, Higher last 4 | 7.47% | 5.21% | 1.21% | -1.09% | 7.15 | -17.19% | 99.21% | 3.18% | 110.77% | | | |
| CALM | 7/19/2022 | AMC | Bull: \$0.17M (100%) Bear: \$5.0M (41%), Bull: \$3.58M (29%), Stock: \$2.38M (20%), Vol: \$1.22M (10%) | Even of 8 | 8.64% | 6.32% | -0.04% | -4.46% | 2.85 | -20.80% | 75.26% | 12.45% | 9.91% | | | |
| ABT | 7/20/2022 | BMO | | Lower 6 of 8 | 3.52% | 3.37% | -0.50% | -4.26% | 4.73 | -9.37% | 15.09% | 0.75% | 7.27% | | | |
| BIB | 7/20/2022 | BMO | Bear: \$4.83M (38%), Vol: \$4.18M (33%), Bull: \$3.8M (30%) | Lower 5 of 8, Lower last 3 | 4.04% | 3.79% | -0.68% | -10.80% | 3.3 | -10.40% | 46.99% | 1.73% | 30.57% | | | |
| BKR | 7/20/2022 | BMO | Bull: \$1.18M (90%), Bear: \$0.14M (10%) | Higher 5 of 8 | 10.24% | 5.71% | 0.56% | -4.25% | 7.25 | -3.76% | 69.84% | 3.35% | 65.13% | | | |
| NDAQ | 7/20/2022 | BMO | Bear: \$1.68M (54%), Bull: \$1.0M (32%), Stock: \$0.42M (14%) | Even of 8, Lower last 3 | 5.57% | 3.79% | -0.09% | -4.53% | 4.19 | -4.70% | 17.46% | 1.71% | 8.29% | | | |
| NTRS | 7/20/2022 | BMO | No Trades Since Last Report | Higher 5 of 8 | 6.72% | 4.40% | 0.55% | -2.37% | 5.59 | -11.70% | 13.20% | 1.50% | 6.60% | | | |
| MKTX | 7/20/2022 | BMO | Bull: \$0.36M (100%) | Lower 5 of 8 | 8.39% | 4.13% | -0.61% | -1.93% | 8.6 | -8.64% | 87.16% | 1.78% | -23.92% | | | |
| LAD | 7/20/2022 | BMO | Bull: \$1.32M (100%) Bull: \$415.13M (52%), Bear: \$323.41M (41%), Vol: \$49.43M (6%), Stock: \$9.28M (1%) | Higher 7 of 8 | 10.87% | 7.74% | 1.74% | 34.10% | 9.94 | -17.68% | 36.16% | 6.01% | 16.00% | | | |
| TSLA | 7/20/2022 | AMC | | Lower 5 of 8 | 7.69% | 7.04% | -2.64% | -19.10% | 12.09 | -13.80% | 1.79% | 3.17% | 6.90% | | | |
| CSX | 7/20/2022 | AMC | Bull: \$1.63M (48%), Bear: \$1.55M (46%), Stock: \$0.2M (6%) | Higher 5 of 8 | 4.67% | 5.41% | 2.21% | 6.08% | 6.68 | -12.90% | 0.18% | 1.36% | 25.80% | | | |
| DFS | 7/20/2022 | AMC | Bear: \$3.29M (50%), Vol: \$1.88M (28%), Bull: \$1.45M (22%) | Even of 8 | 5.54% | 6.27% | -0.07% | 6.02% | 10.56 | -10.07% | 95.05% | 1.47% | -17.56% | | | |
| EFX | 7/20/2022 | AMC | Bear: \$0.56M (65%), Bull: \$0.31M (35%) | Lower 6 of 8, Lower last 2 | 8.60% | 7.24% | -2.70% | -6.26% | 6.03 | -14.90% | 77.45% | 2.02% | 28.88% | | | |
| STLD | 7/20/2022 | AMC | Bull: \$3.83M (89%), Bear: \$0.49M (11%) Bull: \$27.87M (59%), Bear: \$15.27M (32%), Vol: \$3.05M (6%), Stock: \$1.39M (3%) | Even of 8 | 10.47% | 5.12% | 0.34% | -3.76% | 8.32 | -5.95% | 57.75% | 3.13% | -22.39% | | | |
| UAL | 7/20/2022 | AMC | | Lower 6 of 8 | 7.86% | 6.38% | -3.62% | -13.17% | 9.58 | -6.46% | 97.50% | 7.28% | 11.27% | | | |
| CCK | 7/20/2022 | AMC | No Trades Since Last Report | Higher 6 of 8 | 6.77% | 5.56% | 1.22% | 6.45% | 7.38 | -14.90% | 7.92% | 4.14% | 16.49% | | | |
| AA | 7/20/2022 | AMC | Bear: \$16.29M (54%), Bull: \$10.58M (35%), Stock: \$3.2M (11%) | Even of 8 | 9.17% | 11.31% | -0.94% | -6.68% | 8.51 | -7.66% | 96.11% | 6.19% | 26.76% | | | |
| KNX | 7/20/2022 | AMC | Bear: \$1.04M (100%) | Even of 8 | 7.87% | 5.50% | -0.82% | -7.02% | 5.63 | -11.38% | 90.30% | 7.53% | 18.68% | | | |
| XM | 7/20/2022 | AMC | Bear: \$0.7M (90%), Bull: \$0.08M (10%) | Higher 4 of 6 | 15.77% | 12.29% | 2.46% | 20.65% | 5.92 | -12.83% | 21.74% | nan | nan | | | |
| SEIC | 7/20/2022 | AMC | No Trades Since Last Report | Lower 7 of 8, Lower last 2 | 6.92% | 6.38% | -4.09% | -39.59% | 5.46 | -15.30% | 72.39% | 1.86% | 24.10% | | | |
| LSTR | 7/20/2022 | AMC | No Trades Since Last Report | Even of 8 | 7.36% | 4.31% | -0.69% | -2.87% | 6.43 | -7.74% | 75.35% | 6.61% | 60.93% | | | |

Earnings Review

| Ticker | Company | Earnings Date | EPS Reported | EPS Consensus | Y/Y Growth | Revenue | | | Forward Guidance |
|-----------------------------|---------------------------------------|---------------|--------------|---------------|------------|------------------------|-------------------------|------------|-------------------|
| | | | | | | Revenue Reported (\$M) | Revenue Consensus (\$M) | Y/Y Growth | |
| AFTER MARKET REPORTS | | | | | | | | | |
| ELS | Equity Lifestyle Properties, Inc. | 7/19/2022 | \$0.64 | \$0.65 | 100.00% | \$365.30 | \$316.20 | 135.33% | |
| IBM | International Business Machines Corp. | 7/18/2022 | \$2.31 | \$2.27 | -0.86% | \$15,540.00 | \$15,185.10 | -17.10% | Reaffirms Outlook |

IBM—Beats on EPS and Revenues, Reaffirms Guidance- In the quarter we delivered good revenue performance with balanced growth across our geographies, driven by client demand for our hybrid cloud and AI offerings. The IBM team executed our strategy well. With our first half results, we continue to expect full-year revenue growth at the high end of our mid-single digit model. We are a faster-growing, focused, disciplined company with sound business fundamentals. Our recurring revenue stream and solid cash generation position us well to continue to invest in R&D, acquire new companies, and strengthen our talent in every part of the business, while also returning value to shareholders through our dividend. The company continues to expect constant currency revenue growth at the high end of its mid-single digit model. The company also expects an additional 3.5-point contribution from incremental sales to Kyndryl. At mid-July 2022 foreign exchange rates, currency is expected to be about a six-point headwind. The company now expects about \$10 billion in consolidated free cash flow.

| Ticker | Company | Earnings Date | EPS Reported | EPS Consensus | Y/Y Growth | Revenue | | |
|------------------------------|-----------------------------|---------------|--------------|---------------|------------|------------------|-----------------|---------------------------------|
| | | | | | | Revenue Reported | Consensus (\$M) | Y/Y Growth |
| BEFORE MARKET REPORTS | | | | | | | | |
| ALLY | Ally Financial Inc | 7/19/2022 | \$1.76 | \$1.86 | -24.46% | \$2,220.00 | \$2,191.81 | 6.47% |
| HAL | Halliburton Company | 7/19/2022 | \$0.49 | \$0.45 | 88.46% | \$5,070.00 | \$4,704.99 | 36.77% |
| HAS | Hasbro, Inc. | 7/19/2022 | \$1.15 | \$0.94 | 9.52% | \$1,340.00 | \$1,372.83 | 1.35% |
| JNJ | Johnson & Johnson | 7/19/2022 | \$2.59 | \$2.54 | 4.44% | \$24,020.00 | \$23,813.48 | 3.04% FY22 Outlook Below Street |
| LMT | Lockheed Martin Corporation | 7/19/2022 | \$6.32 | \$1.74 | -11.36% | \$15,450.00 | \$16,049.18 | -9.27% FY22 Below Street |
| MAN | ManpowerGroup Inc. | 7/19/2022 | \$2.29 | \$2.32 | 13.37% | \$5,070.00 | \$5,269.62 | -3.92% |
| NVS | Novartis AG (ADR) | 7/19/2022 | \$1.56 | \$1.52 | -6.02% | \$12,780.00 | \$13,047.75 | -3.87% |

ALLY – Misses EPS, Beats Revenues - Consumer auto originations of \$13.3 billion, from 3.3 million decided applications | Highest quarterly originations since 2006; Retail balances of \$131.2 billion, down 4% quarter over quarter (QoQ) driven by elevated tax outflows; up 1% YoY; Ally Home® direct-to-consumer mortgage originations of \$0.9 billion | Lower originations reflecting higher interest rate environment; Ally Invest net customer assets of \$13.5 billion, down 18% YoY due to market trends | 518K active accounts, up 5% YoY; Ally delivered strong operational results again this quarter, including net financing revenues growing for the eighth consecutive quarter and net interest margin exceeding four percent for the first time in company history. Newer businesses like Ally Credit Card are steadily growing and helping offset more cyclical businesses, like Ally Home. Net income attributable to common shareholders was \$454 million in the quarter, compared to \$900 million in the second quarter of 2021, as higher net financing revenue was more than offset by higher provision for credit losses, lower other revenue and higher noninterest expenses.

JNJ – Beats EPS and Revenues but Lowers Outlook on US Dollar Headwinds - Consumer Health worldwide adjusted operational sales increased 2.9%, contributors to growth include upper respiratory and analgesic products in the international market of our over-the-counter franchise as well as IMODIUM in digestive health products and NEUTROGENA in international Skin Health/Beauty. Pharmaceutical worldwide adjusted operational sales grew 12.4% driven by DARZALEX (daratumumab), a biologic for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis, and INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults. MedTech worldwide adjusted operational sales grew 3.4% driven primarily by contact lenses and surgical vision products in our Vision franchise, and electrophysiology products in our Interventional Solutions business.

HAS – Beats EPS, Misses Revenues - Delivered strong second quarter results, driving mid-single digit revenue growth absent foreign exchange and 200 basis points of adjusted operating margin expansion. Wizards of the Coast turned in its biggest quarter ever, led by 15% growth in tabletop gaming and 11% growth in MAGIC: THE GATHERING across platforms. We also significantly enhanced our digital play and direct-to-fan capabilities with the acquisition of D&D Beyond which will serve as an important growth driver for Hasbro's industry leading fantasy gaming portfolio. Foreign exchange is impacting our top line revenue growth, but our teams are executing well to meet demand and drive profit.

LMT – Misses EPS and Revenues, Lowers Outlook - Although revenue in the period was affected by supply chain impacts and the timing of customer contract negotiations, our cost management initiatives resulted in margin expansion. Moreover, our robust cash generation also continues to provide the resources to invest in building the foundation for future revenue and margin growth opportunities through our classified program capex projects, hypersonics development efforts, and our 21st Century Security and internal Digital Transformation initiatives. Aeronautics' net sales during the quarter ended June 26, 2022 decreased \$804 million, or 12%, compared to the same period in 2021. Net sales decreased by approximately \$945 million for the F-35 program due to lower volume on production contracts as a result of supply chain performance delays and delays in receiving additional contractual authorization and funding under the Lots 15-17 contract, and about \$50 million on the F-16 program due to lower volume on sustainment contracts and an unfavorable profit adjustment on a production contract in the second quarter of 2022 as a result of manufacturing line ramp up delays, partially offset by higher volume on production contracts. MFC's net sales during the quarter ended June 26, 2022 decreased \$197 million, or 7%, compared to the same period in 2021. The decrease was primarily attributable to lower net sales of approximately \$155 million for sensors and global sustainment programs primarily due to lower volume on SOF GLSS as a result of troop withdrawals from Afghanistan and lower net favorable profit adjustments due to close out activities in the second quarter of 2021 related to the Warrior Capability Sustainment Program (Warrior); and about \$45 million for tactical and strike missile programs due to lower volume (air dominance weapon systems). RMS' net sales during the quarter ended June 26, 2022 decreased \$230 million, or 5%, compared to the same period in 2021. The decrease was primarily attributable to lower net sales of approximately \$100 million for Sikorsky helicopter programs due to lower production volume (Black Hawk); about \$80 million for integrated warfare systems and sensors (IWSS) programs due to lower volume (Littoral Combat Ship (LCS) and Advanced Hawkeye); and approximately \$55 million for various C6ISR (command, control, communications, computers, cyber, combat systems, intelligence, surveillance, and reconnaissance) programs due to lower volume. Space's net sales during the quarter ended June 26, 2022 decreased \$352 million, or 11%, compared to the same period in 2021.

Disclosures

Disclaimer:

Not Investment Advice or Recommendation

Any descriptions "to buy", "to sell", "long", "short" or any other trade related terminology should not be seen as a recommendation. The Author may or may not take positions in any of the names mentioned, and is not obligated to disclose positions, nor position sizes.

Content is for informational and educational purposes only, and is not to be construed as specific investment advice or recommendations. You alone will need to evaluate the merits and risks associated with the use of this content. Decisions based on information provided are your sole responsibility, and before making any decision on the basis of this information, you should consider (with or without the assistance of a financial and/or securities adviser) whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. Investors should seek qualified professional financial advice regarding the suitability of investing in any securities or following any investment strategies.

No reference to any specific security constitutes a recommendation to buy, sell or hold that security or any other security. Nothing constitutes investment advice or offers any opinion with respect to the suitability of any security, and the views expressed on this website should not be taken as advice to buy, sell or hold any security. In preparing the information contained in this website, OptionsHawk has not taken into account the investment needs, objectives and financial circumstances of any particular investor. This information does not consider the specific investment objectives, financial situation and particular needs of any specific recipient of this information and investments discussed may not be suitable for all investors

For example, and, as always, be aware that market timing and conditions may materially affect trades of this nature: The above is an example of a trade idea, but you must be aware of the risks of trading. As we have disclosed, we are not licensed, and we are not giving specific securities advice for your portfolio. We are merely providing examples and education of strategies. We always advise people to get professional advice, and we are not recommending any particular trade or security or soliciting any trade or security.